Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol–Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database

IMPORTANCE: Low-density lipoprotein cholesterol (LDL-C)–lowering therapies are a cornerstone of prevention in atherosclerotic cardiovascular disease. With the introduction of generic formulations and the release of new therapies, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Cardiol
Autors principals: Sumarsono, Andrew, Lalani, Hussain S., Vaduganathan, Muthiah, Navar, Ann Marie, Fonarow, Gregg C., Das, Sandeep R., Pandey, Ambarish
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2020
Matèries:
Brief Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7489407/
https://ncbi.nlm.nih.gov/pubmed/32902560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.3723
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars